Cargando…

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study

BACKGROUND: Multiple clinical trials demonstrate consistent but modest benefit of adjuvant extended endocrine therapy (EET) in HR + breast cancer patients. Predictive biomarkers to identify patients that benefit from EET are critical to balance modest reductions in risk against potential side effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Sgroi, Dennis C., Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle, Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Taylor, Karen J., Brachtel, Elena, Pirrie, Sarah, Schnabel, Catherine A., Rea, Daniel, Bartlett, John M. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758861/
https://www.ncbi.nlm.nih.gov/pubmed/36527133
http://dx.doi.org/10.1186/s13058-022-01589-x
_version_ 1784852129303756800
author Sgroi, Dennis C.
Treuner, Kai
Zhang, Yi
Piper, Tammy
Salunga, Ranelle
Ahmed, Ikhlaaq
Doos, Lucy
Thornber, Sarah
Taylor, Karen J.
Brachtel, Elena
Pirrie, Sarah
Schnabel, Catherine A.
Rea, Daniel
Bartlett, John M. S.
author_facet Sgroi, Dennis C.
Treuner, Kai
Zhang, Yi
Piper, Tammy
Salunga, Ranelle
Ahmed, Ikhlaaq
Doos, Lucy
Thornber, Sarah
Taylor, Karen J.
Brachtel, Elena
Pirrie, Sarah
Schnabel, Catherine A.
Rea, Daniel
Bartlett, John M. S.
author_sort Sgroi, Dennis C.
collection PubMed
description BACKGROUND: Multiple clinical trials demonstrate consistent but modest benefit of adjuvant extended endocrine therapy (EET) in HR + breast cancer patients. Predictive biomarkers to identify patients that benefit from EET are critical to balance modest reductions in risk against potential side effects of EET. This study compares the performance of the Breast Cancer Index, BCI (HOXB13/IL17BR, H/I), with expression of estrogen (ER), progesterone (PR), and androgen receptors (AR), and Ki67, for prediction of EET benefit. METHODS: Node-positive (N+) patients from the Trans-aTTom study with available tissue specimen and BCI results (N = 789) were included. Expression of ER, PR, AR, and Ki67 was assessed by quantitative immunohistochemistry. BCI (H/I) gene expression analysis was conducted by quantitative RT-PCR. Statistical significance of the treatment by biomarker interaction was evaluated by likelihood ratio tests based on multivariate Cox proportional models, adjusting for age, tumor size, grade, and HER2 status. Pearson’s correlation coefficients were calculated to evaluate correlations between BCI (H/I) versus ER, PR, AR, Ki67 and AR/ER ratio. RESULTS: EET benefit, measured by the difference in risk of recurrence between patients treated with tamoxifen for 10 versus 5 years, is significantly associated with increasing values of BCI (H/I) (interaction P = 0.01). In contrast, expression of ER (P = 0.83), PR (P = 0.66), AR (P = 0.78), Ki67 (P = 0.87) and AR/ER ratio (P = 0.84) exhibited no significant relationship with EET benefit. BCI (H/I) showed a very weak negative correlation with ER (r = − 0.18), PR (r = − 0.25), and AR (r = − 0.14) expression, but no correlation with either Ki67 (r = 0.04) or AR/ER ratio (r = 0.02). CONCLUSION: These findings are consistent with the growing body of evidence that BCI (H/I) is significantly predictive of response to EET and outcome. Results from this direct comparison demonstrate that expression of ER, PR, AR, Ki67 or AR/ER ratio are not predictive of benefit from EET. BCI (H/I) is the only clinically validated biomarker that predicts EET benefit. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-022-01589-x.
format Online
Article
Text
id pubmed-9758861
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97588612022-12-18 Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study Sgroi, Dennis C. Treuner, Kai Zhang, Yi Piper, Tammy Salunga, Ranelle Ahmed, Ikhlaaq Doos, Lucy Thornber, Sarah Taylor, Karen J. Brachtel, Elena Pirrie, Sarah Schnabel, Catherine A. Rea, Daniel Bartlett, John M. S. Breast Cancer Res Research BACKGROUND: Multiple clinical trials demonstrate consistent but modest benefit of adjuvant extended endocrine therapy (EET) in HR + breast cancer patients. Predictive biomarkers to identify patients that benefit from EET are critical to balance modest reductions in risk against potential side effects of EET. This study compares the performance of the Breast Cancer Index, BCI (HOXB13/IL17BR, H/I), with expression of estrogen (ER), progesterone (PR), and androgen receptors (AR), and Ki67, for prediction of EET benefit. METHODS: Node-positive (N+) patients from the Trans-aTTom study with available tissue specimen and BCI results (N = 789) were included. Expression of ER, PR, AR, and Ki67 was assessed by quantitative immunohistochemistry. BCI (H/I) gene expression analysis was conducted by quantitative RT-PCR. Statistical significance of the treatment by biomarker interaction was evaluated by likelihood ratio tests based on multivariate Cox proportional models, adjusting for age, tumor size, grade, and HER2 status. Pearson’s correlation coefficients were calculated to evaluate correlations between BCI (H/I) versus ER, PR, AR, Ki67 and AR/ER ratio. RESULTS: EET benefit, measured by the difference in risk of recurrence between patients treated with tamoxifen for 10 versus 5 years, is significantly associated with increasing values of BCI (H/I) (interaction P = 0.01). In contrast, expression of ER (P = 0.83), PR (P = 0.66), AR (P = 0.78), Ki67 (P = 0.87) and AR/ER ratio (P = 0.84) exhibited no significant relationship with EET benefit. BCI (H/I) showed a very weak negative correlation with ER (r = − 0.18), PR (r = − 0.25), and AR (r = − 0.14) expression, but no correlation with either Ki67 (r = 0.04) or AR/ER ratio (r = 0.02). CONCLUSION: These findings are consistent with the growing body of evidence that BCI (H/I) is significantly predictive of response to EET and outcome. Results from this direct comparison demonstrate that expression of ER, PR, AR, Ki67 or AR/ER ratio are not predictive of benefit from EET. BCI (H/I) is the only clinically validated biomarker that predicts EET benefit. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-022-01589-x. BioMed Central 2022-12-16 2022 /pmc/articles/PMC9758861/ /pubmed/36527133 http://dx.doi.org/10.1186/s13058-022-01589-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sgroi, Dennis C.
Treuner, Kai
Zhang, Yi
Piper, Tammy
Salunga, Ranelle
Ahmed, Ikhlaaq
Doos, Lucy
Thornber, Sarah
Taylor, Karen J.
Brachtel, Elena
Pirrie, Sarah
Schnabel, Catherine A.
Rea, Daniel
Bartlett, John M. S.
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
title Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
title_full Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
title_fullStr Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
title_full_unstemmed Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
title_short Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
title_sort correlative studies of the breast cancer index (hoxb13/il17br) and er, pr, ar, ar/er ratio and ki67 for prediction of extended endocrine therapy benefit: a trans-attom study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758861/
https://www.ncbi.nlm.nih.gov/pubmed/36527133
http://dx.doi.org/10.1186/s13058-022-01589-x
work_keys_str_mv AT sgroidennisc correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy
AT treunerkai correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy
AT zhangyi correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy
AT pipertammy correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy
AT salungaranelle correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy
AT ahmedikhlaaq correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy
AT dooslucy correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy
AT thornbersarah correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy
AT taylorkarenj correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy
AT brachtelelena correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy
AT pirriesarah correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy
AT schnabelcatherinea correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy
AT readaniel correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy
AT bartlettjohnms correlativestudiesofthebreastcancerindexhoxb13il17branderprararerratioandki67forpredictionofextendedendocrinetherapybenefitatransattomstudy